611 Health status and utilization of health care programs of long-term survivors: survivorship clinic for long-term survivors with gynecological cancer

Abstract

Introduction/Background

Aim of the study is to establish a survivorship clinic for long-term survivors (LTS) with gynaecological cancer as a new form of care to improve quality of life. This preliminary analysis aims to evaluate their health status to gain further insight into LTS' needs.

Methodology

Non-randomized, controlled, multi-center, open intervention study with two parallel groups (n=180 per group). The intervention group takes part in the holistic survivorship clinic at Charité – Universitätsmedizin Berlin; the control group (recruited by the North-East German Society for Gynecological Oncology) receives routine follow-up care. Main inclusion criterion: gynaecological cancer at least five years ago. Primary endpoint is health-specific quality of life (SF-36) after 12 months; secondary endpoints include frequency and severity of long-term side effects.

Results

A total of 373 LTS could be recruited: ovarian (n=249; 67%), cervical (n=83; 22%), endometrial cancer (n=41; 11%). Last patient-out will be 06/2024. Main comorbidities were hypertension (35%), arthrosis (33%) and hypothyroidism (24%). Comedications were documented in 80% of cases. Prior to recruitment, one-third of patients (35%) had been hospitalized within the preceding year, and 24% visited the emergency department. LTS had a median number of 12 physician contacts within one year (range: 1–160 consultations). Most frequent long-term side effects in the intervention group (n=192) were lymphedema (53%), vaginal dryness (50%), gastrointestinal symptoms (45%), psycho-oncological need (43%), memory problems (43%), polyneuropathy (42%) and sleeping disorders (42%). Altogether, 90 received optional specialized survivorship care from neurology (recommendations: n=147), 86 from mental health (recommendations: n=153), 52 from the fatigue centre (recommendations: n=108), and 43 from sexual medicine.

Conclusion

LTS still experience a wide range of (tumor-/therapy-related) symptoms. Specialized survivorship care may help to coordinate health care for LTS with the aim of promoting physical and mental health in order to improve quality of life.

Disclosures

Kommoss S: Receipt of grants/research supports: GSK Receipt of honoraria or consultation fees: GSK, Eisai, Astra Zeneca, MSD Liebrich C: Receipt of honoraria or consultation fees: Roche, Tesaro, GSK, MSK, NCO - New Concept Oncology Schmalfeldt B: Receipt of grants/research supports: Astra Zeneca, DaiichiSankyo, Roche, GSK, MSD, Eisai, MedConcept Receipt of honoraria or consultation fees: Astra Zeneca, DaiichiSankyo, Roche, GSK, MSD, Eisai, MedConcept Wimberger P: Receipt of grants/research supports: Amgen, GSK, Clovis, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Pierre Fabre Receipt of honoraria or consultation fees: AstraZeneca, MSD, Eisai, Novartis, Roche, Amgen, Clovis, Pfizer, Gilliad, Lilly Sehouli J: Receipt of grants/research supports: AstraZeneca, Clovis Oncology, Merck, Bayer, PharmaMar, Pfizer, Tesaro, MSD Oncology, Roche Receipt of honoraria or consultation fees: AstraZeneca, Clovis Oncology, PharmaMar, Merck, Pfizer, Tesaro, MSD Oncology, Lilly, Novocure, J&J, Roche, Ingress Health, Riemser, Sobi, GSK, Novartis, Eisai, Olympus Medical Systems, Pfizer, Teva, Bayer